Your browser doesn't support javascript.
loading
The prognostic impact of magnesium in acute heart failure is different according to the presence of diabetes mellitus.
Cidade-Rodrigues, Catarina; Cunha, Filipe M; Elias, Catarina; Carreira, Marta; Barroso, Isaac; Bettencourt, Paulo; Lourenço, Patrícia.
Afiliación
  • Cidade-Rodrigues C; Endocrinology Department, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal.
  • Cunha FM; Endocrinology Department, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal.
  • Elias C; Internal Medicine Department, Centro Hospitalar e Universitário do São João, Porto, Portugal.
  • Carreira M; Internal Medicine Department, Centro Hospitalar e Universitário do São João, Porto, Portugal.
  • Barroso I; Clinical Pathology Department, Centro Hospitalar e Universitário do São João, Porto, Portugal.
  • Bettencourt P; Internal Medicine Department, Hospital CUF, Porto, Portugal.
  • Lourenço P; Faculty of Medicine, University of Porto, Porto, Portugal.
Porto Biomed J ; 7(6): e197, 2022.
Article en En | MEDLINE | ID: mdl-37152077
ABSTRACT

Background:

Hypermagnesemia predicts mortality in chronic heart failure (HF); however, in acute HF, magnesium does not seem to be outcome-associated. Diabetes mellitus (DM) frequently associates with altered magnesium status. We hypothesized that DM might influence the prognostic impact of magnesium in acute HF.

Methods:

This is a retrospective cohort study of hospitalized patients with acute HF. Patients without data on admission serum magnesium were excluded. Follow-up 1 year from hospital admission. Primary end point all-cause mortality. Patients were divided according to median serum magnesium (1.64 mEq/L). The Kaplan-Meier survival method was used to determine survival curves according to magnesium levels. The analysis was stratified according to the presence of DM. A multivariable Cox regression analysis was used to study the prognostic impact of magnesium.

Results:

We studied 606 patients. The mean age was 76 ± 12 years, 44.1% were male, 50.7% had DM, and 232 (38.3%) died during follow-up. Median magnesium was 1.64 (1.48-1.79) mEq/L. Patients with magnesium ≥1.64 mEq/L had higher 1-year mortality [141 (46.4%) vs 91 (30.1%), P < .001]. After adjustments for age, sex, history of atrial fibrillation, systolic blood pressure, heart rate, ischemic etiology, B-type natriuretic peptide, estimated glomerular filtration rate, alcohol consumption, antihyperglycaemic agents or glycated hemoglobin, admission glycemia, New York Heart Association class IV, and severe left ventricle systolic dysfunction, serum magnesium ≥1.64 mEq/L was associated with higher mortality only in patients with DM HR 1.89 (95% confidence interval 1.19-3.00), P = .007, and 1.27 (95% confidence interval 0.83-1.94) and P = .26 for non-DM patients. The results were similar if magnesium was analyzed as a continuous variable. Per 0.1 mEq/L increase in magnesium levels, patients with DM had 13% increased risk of 1-year mortality.

Conclusions:

Higher magnesium levels were associated with worse prognosis only in HF patients with DM.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Porto Biomed J Año: 2022 Tipo del documento: Article País de afiliación: Portugal

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Porto Biomed J Año: 2022 Tipo del documento: Article País de afiliación: Portugal